Retroviral delivery of peptide modulators of cellular functions

Molecular Therapy

Volumn 1, Issue 5, 2000, Pages 438-447

  Lorens, J B ^a   Bennett, M K ^a   Pearsall, D M ^a   Throndset, W R ^a   Rossi, A B ^a   Armstrong, R J ^a   Fox, B P ^a   Chan, E H ^a   Luo, Y ^a   Masuda, E ^a   Ferrick, D A ^a   Anderson, D C ^a   Payan, D G ^a   Nolan, G P ^b  

^a RIGEL PHARMACEUTICALS INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN; PRIMER DNA;

ANIMAL; ARTICLE; BIOSYNTHESIS; BONE MARROW; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; EXOCYTOSIS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HELA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA CELL LINE; MASS SPECTROMETRY; MAST CELL; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN MOTIF; RETROVIRUS; SERODIAGNOSIS; VIROLOGY; WESTERN BLOTTING;

AMINO ACID MOTIFS; ANIMALS; BLOTTING, WESTERN; BONE MARROW; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA PRIMERS; ENZYME INHIBITORS; EXOCYTOSIS; G1 PHASE; G2 PHASE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; JURKAT CELLS; LUMINESCENT PROTEINS; MASS SPECTROMETRY; MAST CELLS; MICROSCOPY, FLUORESCENCE; PRECIPITIN TESTS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROVIRIDAE; TRANSDUCTION, GENETIC;

EID: 0034183694     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0063     Document Type: Article

References (40)

1. Hitoshi, Y., Lorens, J., Kitada, S. I., Fisher, J., LaBarge, M., Ring, H. Z., Francke, U., Reed, J. C., Kinoshita, S., and Nolan, G. P. (1998). Toso, a cell surface, specific regulator of Fas-induced apoptosisin T cells. Immunity 8: 461-471.
2. Swift, S. E., Lorens, J. B., Achacoso, P., and Nolan, G. P. (1999). In Current Protocols in Immunology (J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, Eds), Vol. 10.17C, pp. 1-17, Wiley, New York.
3. Murray, A., and Hunt, T. (1993). The Cell Cycle. Freeman, New York.
4. Harper, J. W. (1997). Cyclin dependent kinase inhibitors. Cancer Surv. 29: 91-107.
5. Xiong, Y., Zhang, H., and Beach, D. (1992). D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514.
6. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993). p21 isa universal inhibitor of cyclin kinases [see comments]. Nature 366: 701-704.
7. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Eledge, S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
8. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA [see comments]. Nature 369: 574-578.
9. Chen, J., Jackson, P. K., Kirschner, M. W., and Dutta, A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386-388.
10. Luo, Y., Hurwitz, J., and Massague, J. (1995). Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375: 159-161.
11. Warbrick, E., Lane, D. P., Glover, D. M., and Cox, L. S. (1995). A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5: 275-282.
12. Gulbis, J. M., Kelman, Z., Hurwitz, J., O'Donnell, M., and Kuriyan, J. (1996). Structure of the C-terminal region of p21 (WAF1/CIP1) complexed with human PCNA. Cell 87: 297-306.
13. Jonsson, Z. O., and Hubscher, U. (1997). Proliferating cell nuclear antigen: More than a clamp for DNA polymerases. BioEssays 19: 967-975.
14. Jonsson, Z. O., Hindges, R., and Hubscher, U. (1998). Regulation of DNA replication and repair proteins through interaction with the front side of proliferating cell nuclear antigen. EMBO J. 17: 2412-2425.
15. Yang, Z. Y., Perkins, N. D., Ohno, T., Nabel, E. G., and Nabel, G. J. (1995). The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo [see comments]. Nat. Med. 1: 1052-1056.
16. Yang, Z. Y., Simari, R. D., Perkins, N. D., San, H., Gordon, D., Nabel, G. J., and Nabel, E. G. (1996). Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA 93: 7905-7910.
17. White, J. R., and Zembryki, D. (1989). Differentiation of second messenger systems in mast cell activation. Agents Actions 27: 410-413.
18. Kitani, S., Teshima, R., Morita, Y., Ito, K., Matsuda, Y., and Nonomura, Y. (1992). Inhibition of IgE-mediated histamine release by myosin light chain kinase inhibitors. Biochem. Biophys. Res. Commun. 183: 48-54.
19. Yamada, K., Jelsema, C. L., and Beaven, M. A. (1992). Certain inhibitors of protein serine/threonine kinases also inhibit tyrosine phosphorylation of phospholipase C gamma 1 and other proteins and reveal distinct roles for tyrosine kinase(s) and protein kinase C in stimulated, rat basophilic RBL-2H3 cells. J. Immunol. 149: 1031-1037.
20. Demo, S. D., Masuda, E., Rossi, A. B., Throndset, B. T., Gerard, A. L., Chan, E. H., Armstrong, R. J., Fox, B. R., Lorens, J. B., Payan, D. G., Scheller, R. H., and Fisher, J. M. (1999). Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay [in process citation]. Cytometry 36: 340-348.
21. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89: 5547-5551.
22. Cayrol, C., Knibiehler, M., and Ducommun, B. (1998). p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320.
23. Chen, J., Peters, R., Saha, P., Lee, P., Theodoras, A., Pagano, M., Wagner, G., and Dutta, A. (1996). A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res. 24: 1727-1733.
24. Andreadis, S. T., Brott, D., Fuller, A. O., and Palsson, B. O. (1997). Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours. J. Virol. 71: 7541-7548.
25. Roa, M., Paumet, F., Le Mao, J., David, B., and Blank, U. (1997). Involvement of the ras-like GTPase rab3d in RBL-2H3 mast cell exocytosisfollowing stimulation via high affinity IgE receptors (Fc epsilonRI). J. Immunol. 159: 2815-2823.
26. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage [in process citation]. Science 282: 1497-1501.
27. Zhang, P., Sun, Y., Hsu, H., Zhang, L., Zhang, Y., and Lee, M. Y. (1998). The interdomain connector loop of human PCNA is involved in a direct interaction with human polymerase delta. J. Bol. Chem. 273: 713-719.
28. Levin, D. S., Bai, W., Yao, N., O'Donnell, M., and Tomkinson, A. E. (1997). An interaction between DNA ligase I and proliferating cell nuclear antigen: Implications for Okazaki fragment synthesis and joining. Proc. Natl. Acad. Sci. USA 94: 12863-12868.
29. Fotedar, R., Mossi, R., Fitzgerald, P., Rousselle, T., Maga, G., Brickner, H., Messier, H., Kasibhatla, S., Hubscher, U., and Fotedar, A. (1996). A conserved domain of the large subunit of replication factor C binds PCNA and acts like a dominant negative inhibitor of DNA replication in mammalian cells. EMBO J. 15; 4423-4433.
30. Warbrick, E., Lane, D. P., Glover, D. M., and Cox, L. S. (1997). Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: A potential mechanism to co-ordinate DNA replication and repair. Oncogene 14: 2313-2321.
31. Hosfield, D. J., Mol, C. D., Shen, B., and Tainer, J. A. (1998). Structure of the DNA repair and replication endonuclease and exonuclease FEN-1: Coupling DNA and PCNA binding to FEN-1 activity. Cell 95: 135-146.
32. Chuang, L. S., Ian, H. I., Koh, T. W., Ng, H. H., Xu, G., and Li, B. F. (1997). Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277: 1996-2000.
33. Warbrick, E. (1998). PCNA binding through a conserved motif. BioEssays 20: 195-199.
34. Oku, T., Ikeda, S., Sasaki, H., Fukuda, K., Morioka, H., Ohtsuka, E., Yoshikawa, H., and Tsurimoto, T. (1998). Functional sites of human PCNA which interact with p21 (Cip1/Waf1), DNA polymerase delta and replication factor C. Genes Cells 3: 357-369.
35. Merrill, B. J., and Holm, C. (1998). The RAD52 recombinational repair pathway is essential in pol30 (PCNA) mutants that accumulate small single-stranded DNA fragments during DNA synthesis. Genetics 148: 611-624.
36. Nakanishi, M., Robetorye, R. S., Pereira-Smith, O. M., and Smith, J. R. (1995). The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J. Biol. Chem. 270: 17060-17063.
37. Ogryzko, V. V., Wong, P., and Howard, B. H. (1997). WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol. Cell. Biol. 17: 4877-4882.
38. Metcalfe, D. D., Baram, D., and Mekori, Y. A. (1997). Mast cells. Physiol. Rev. 77: 1033-1079.
39. Marquardt, D. L., and Walker, L. L. (1994). Inhibition of protein kinase A fails to alter mast cell adenosine responsiveness. Agents Actions 43: 7-12.
40. Weston, M. C., and Peachell, P. T. (1998). Regulation of human mast cell and basophil function by cAMP. Gen. Pharmacol. 31: 715-719.